Cancer patients frequently suffer electrolyte abnormalities that complicate the management of their condition. The most commonly occurring derangement is hyponatremia, while hypercalcemia, hypokalemia, and hypophosphatemia are also encountered. The etiology of these abnormalities is often identifiable, and early diagnosis and management can prevent delays in necessary anti-cancer therapies.
UpadhyayAJaberBLMadiasNEIncidence and prevalence of hyponatremia. Am J Med20061197 Suppl 1S30–S35
2.
WaikarSSMountDBCurhanGCMortality after hospitalization with mild, moderate, and severe hyponatremia. Am J Med20091229857–865
3.
BerghmansTPaesmansMBodyJJA prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer200083192–197
4.
DoshiSMShahPLeiXLahotiASalahudeenAKHyponatremia in hospitalized cancer patients and its impact on clinical outcomes. Am J Kidney Dis2012592222–228
5.
CastilloJJGlezermanIGBoklageSH. The occurrence of hyponatremia and its importance as a prognostic factor in a cross-section of cancer patients. BMC Cancer2016161564
6.
SchwartzWBBennettWCurelopSBartterFCA syndrome of renal sodium loss and hyponatremia probably resulting from inappropriate secretion of antidiuretic hormone. Am J Med1957234529–542
7.
BaumannGLopez-AmorEDingmanJFPlasma arginine vasopressin in the syndrome of inappropriate antidiuretic hormone secretion. Am J Med197252119–24
8.
SørensenJBAndersenMKHansenHHSyndrome of inappropriate secretion of antidiuretic hormone (SIADH) in malignant disease. J Intern Med1995238297–110
9.
CamplingBGSardaIRBaerKA. Secretion of atrial natriuretic peptide and vasopressin by small cell lung cancer. Cancer199575102442–2451
10.
BlissDPJrBatteyJFLinnoilaRIBirrerMJGazdarAFJohnsonBEExpression of the atrial natriuretic factor gene in small cell lung cancer tumors and tumor cell lines. J Natl Cancer Inst1990824305–310
11.
OnitiloAAKioEDoiSATumor-related hyponatremia. Clin Med Res200754228–237
12.
BauseweinCKühnbachRHaberlandBAdrenal insufficiency caused by bilateral adrenal metastases a rare treatable cause for recurrent nausea and vomiting in metastatic breast cancer. Onkologie2006295203–205
13.
HamdiTLattaSJalladBKheirFAlhosainiMNPatelACisplatin-induced renal salt wasting syndrome. South Med J20101038793–799
14.
HainsworthJDWorkmanRGrecoFAManagement of the syndrome of inappropriate antidiuretic hormone secretion in small cell lung cancer. Cancer1983511161–165
15.
SalahudeenAKAliNGeorgeMLahotiAPallaSTolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety. Cancer20141205744–751
16.
PetereitCZabaOTeberI. A rapid and efficient way to manage hyponatremia in patients with SIADH and small cell lung cancer: treatment with tolvaptan. BMC Pulm Med201313551–6
17.
De las PeñasRPonceSHenaoF. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan. Support Care Cancer2016241499–507
18.
NewmanEMBouvetMBorgehiSHeroldDADeftosLJCauses of hypercalcemia in a population of military veterans in the United States. Endocr Pract2006125535–541
19.
RalstonSHGallacherSJPatelUCampbellJBoyleITCancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med19901127499–504
20.
LameireNVan BiesenWVanholderRElectrolyte disturbances and acute kidney injury in patients with cancer. Semin Nephrol2010306534–547
21.
WangWLiCKwonTH. Reduced expression of renal Na+ transporters in rats with PTH-induced hypercalcemia. Am J Physiol Renal Physiol20042863F534–F545
22.
McCauleyLKMartinTJTwenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res20122761231–1239
23.
DonovanPJAchongNGriffinKGalliganJPretoriusCJMcLeodDSPTHrP-mediated hypercalcemia: causes and survival in 138 patients. J Clin Endocrinol Metab201510052024–2029
24.
HameedABradyJJDowlingPClynesMOGormanPBone disease in multiple myeloma: pathophysiology and management. Cancer Growth Metastasis20147733–42
25.
LeGrandSBLeskuskiDZamaINarrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med20081494259–263
26.
RossJRSaundersYEdmondsPM. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess2004841–176
27.
KyleRAYeeGCSomerfieldMRet al;American Society of Clinical Oncology. American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol200725172464–2472
28.
HuMIGlezermanIGLeboulleuxS. Denosumab for treatment of hypercalcemia of malignancy. J Clin Endocrinol Metab20149993144–3152
29.
MiltiadousGChristidisDKalogirouMElisafMCauses and mechanisms of acid-base and electrolyte abnormalities in cancer patients. Eur J Intern Med20081911–7
30.
WulfGGJahns-StreubelGStrutzF. Paraneoplastic hypokalemia in acute myeloid leukemia: a case of renin activity in AML blast cells. Ann Hematol1996733139–141
31.
AbbasAMirzaMMGantiAKTendulkarKRenal Toxicities of Targeted Therapies. Target Oncol2015104487–499
32.
IzzedineHBahledaRKhayatD. Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol2010733213–219
33.
WanchooRJhaveriKDDerayGLaunay-VacherVRenal effects of BRAF inhibitors: a systematic review by the Cancer and the Kidney International Network. Clin Kidney J201692245–251
34.
AlemánJOFarookiAGirotraMEffects of tyrosine kinase inhibition on bone metabolism: untargeted consequences of targeted therapies. Endocr Relat Cancer2014213R247–R259
35.
Jan de BeurSMTumor-induced osteomalacia. JAMA2005294101260–1267
